Impact of pharmacokinetics of Cabozantinib on clinical response and adverse event in patients with hepatocellular carcinoma

Impact of pharmacokinetics of Cabozantinib on clinical response and adverse event in patients with hepatocellular carcinoma - Pharmacokinetics and clinical effect of Cabozantinib

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043775

Enrollment

Registered

2021-03-29

Start date

2021-03-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Performance Status 0 or 1 (ECOG) 2. Child-Pugh class A or B 3. Refractory to systemic chemotherapy to the hepatocellular carcinoma.

Exclusion criteria

Exclusion criteria: Patients regarded as inappropriate subject

Design outcomes

Primary

Measure	Time frame
To clarify the relationship between the exposure of cabozantinib and the clinical response during the treatment.	—

Secondary

Measure	Time frame
To clarify the relationship between the exposure of cabozantinib and the development of adverse events during the treatment.	—

Countries

Japan

Contacts

Public ContactMiyuki Katsuki

Juntendo University Nerima Hospital GCP center

gcp@juntendo-nerima.jp0359233111

Outcome results